Geron Corporation
HealthcareNASDAQ:GERN · NASDAQ Global Select
+$0.01 today
Vol 8.10M · Avg 16.47M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-38.0%
avg -54.2%
ROIC
-11.3%
avg -38.6%
ROA
-15.0%
avg -31.7%
Analysis
ROIC is currently the strongest return metric at -11.3% versus its period average of -38.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Joseph Emile Eid | Executive Vice President of Research & Development and Chief Medical Officer | $1.00M | — | 59 | $2.22M | 0.35% |
Michelle J. Robertson | Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer | $810,552.00 | — | 59 | $220,000.00 | 0.03% |
Harout Semerjian | Chief Executive Officer, President & Director | $526,355.00 | — | 56 | $0.00 | <0.01% |
Timothy Williams | Executive Vice President, Chief Legal Officer & Corporate Secretary | $485,317.00 | — | 49 | $2.50M | 0.39% |
Ahmed ElNawawi | Executive Vice President & Chief Commercial Officer | $307,934.00 | — | 45 | $10,000.00 | <0.01% |
Aron Feingold | Vice President of Investor Relations & Corporate Communications | — | — | — | — | — |
Shannon Odam | Executive Vice President & Chief People Officer | — | — | 51 | — | — |
Dawn Schottlandt | Senior Vice President of Investor Relations & Corporate Affairs | — | — | — | $220,000.00 | 0.03% |
Bryan Ridgell | Senior Vice President of Portfolio & Project Management and Chief of Staff | — | — | — | $180,000.00 | 0.03% |
Shanthakumar Tyavanagimatt | Senior Vice President & Chief Technical Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$19,118.70
Net Sentiment
$19,118.70
Net selling
Most Active
ROBERTSON MICHELLE
1 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 1 sells worth $19,118.70 over the last 12 months. That adds up to net selling of $19,118.70. ROBERTSON MICHELLE was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +66.7% (15yr)1 analysts |
| Revenue | N/A | N/A | +137.7% | +24.0% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | +83.9% (15yr)2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +137.7% over three years. Forward estimates point to Net Income at +83.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Day One Biopharmaceuticals, Inc.
DAWN
$2.22B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.61B
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.45B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.42B
Savara Inc.
NASDAQ:SVRA
$1.08B
Replimune Group, Inc.
NASDAQ:REPL
$733.24M
Valneva SE
NASDAQ:VALN
$507.78M
Arvinas, Inc.
NASDAQ:ARVN
$489.07M
Rezolute, Inc.
NASDAQ:RZLT
$385.17M
LENZ Therapeutics, Inc.
NASDAQ:LENZ
$212.27M
Who manages GERN?
Geron Corporation (GERN) lists 10 active executives. The top listed executive is Joseph Emile Eid, Executive Vice President of Research & Development and Chief Medical Officer.
Are GERN insiders buying or selling?
Recent insider activity shows net buying of $76.61M.
Explore More
Continue the stock analysis
Jump to another research area for this company.